Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ApoptiCIDe-RGT-MitoX-003
- Development stage
- Preclinical
- Lead developer
- Phoenix SENOLYTIX
- Modality
- Gene Therapies
- Administration
- Intravenous
01
Overview
ApoptiCIDe-RGT-MitoX-003 is a preclinical-stage regulated gene therapy (RGT) program being developed by Phoenix SENOLYTIX for the treatment of various cancer indications. The therapy utilizes a regulated gene delivery platform to express the PTC-2110 oncopeptide, which is also referred to as the MitoXcel oncopeptide. This therapeutic approach is designed to selectively induce apoptosis in malignant cells, potentially through mitochondrial-targeted pathways as suggested by the MitoXcel nomenclature. The 'ApoptiCIDe' platform represents the company's core technology for controlled gene expression of pro-apoptotic agents to eliminate cancer cells while minimizing off-target effects.
- Other names
- ApoptiCIDe-RGT-MitoX-003ApoptiCIDe-RGT-MitoX003ApoptiCIDe-RGT-MitoX 003PTC-2110PTC2110PTC 2110MitoXcel oncopeptide
02
Targets
NADH:ubiquinone oxidoreductase (Mitochondrial Complex I)iCasp9 (Inducible caspase-9)
Beyond the preview
Go deeper on ApoptiCIDe-RGT-MitoX-003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ApoptiCIDe-RGT-MitoX-003.